Pine Brook to Acquire Triumph Capital Advisors, a Leading CLO Manager, from Triumph Bancorp
Mar 30, 2017 21:42 pm UTC| Business
DALLAS and NEW YORK, March 30, 2017 -- Pine Brook, an investment firm focused on building businesses in the financial services and energy sectors, and Triumph Bancorp, Inc. (NASDAQ:TBK) today announced the signing of a...
Mar 30, 2017 21:34 pm UTC| Business
MIDLAND, Texas, March 30, 2017 -- Legacy Reserves LP ("Legacy") (Nasdaq:LGCY) today announced the semi-annual borrowing base review under its $1.5 billion secured revolving credit facility resulted in the reaffirmation...
Mar 30, 2017 21:30 pm UTC| Business
NEW YORK, March 30, 2017 -- Faruqi Faruqi, LLP, a leading national securities law firm, reminds investors in Global Brokerage, Inc., formerly known as FXCM Inc., (“FXCM” or the “Company”) (NASDAQ:FXCM) of the April 10,...
Propel Media Reports Fourth Quarter and Full Year 2016 Financial Results
Mar 30, 2017 21:28 pm UTC| Business
IRVINE, Calif., March 30, 2017 -- Propel Media, Inc. (OTCPink:PROM), a performance focused digital media and advertising company,today announced its financial results for the fourth quarter and full year ended December...
A. M. Castle & Co. Announces Date for Fourth Quarter 2016 Earnings Release – Friday, April 7th, 2017
Mar 30, 2017 21:15 pm UTC| Business
OAK BROOK, Ill., March 30, 2017 -- A. M. Castle Co. (OTCQB:CASL), a global distributor of specialty metal and supply chain services, announced today that it will release fourth quarter results for the period ended...
Lingerie Fighting Championships Goes Hollywood
Mar 30, 2017 21:13 pm UTC| Business
LAS VEGAS, March 30, 2017 -- Lingerie Fighting Championships, Inc. (“LFC”) (OTC:BOTY) announced today that several of their fighters will be appearing in an upcoming feature film called ‘Gladiatrix: Crescent Moon’. The...
Mar 30, 2017 21:00 pm UTC| Business
-- European Patent Office indicates that no opposition to Catalyst’s patent has been filed -- -- INC Research selected as CRO for Phase 2/3 efficacy clinical trial of Factor VIIa, marzeptacog alfa (activated); trial...